semaglutide news today 2025 Semaglutide just got FDA-approved for

This condition, known as hypoglycemia, can cause dizziness, confusion, and fainting

The Evolution of GLP-1 Medications Semaglutide originally gained fame as an injectable treatment for type 2 diabetes and later as a high-dose injection (Wegovy) for weight loss

14,38,39 Several therapies currently in clinical development target glucagon receptors in addition to incretin receptors due to the effects of glucagon on reducing food intake and increasing energy expenditure

I was my first guinea pig, she said

Semaglutide is approved for once-weekly administration

Key Details of the GLP-1 Bridge Program Timeline Start date: July 1, 2026 End date: December 31, 2027 Transition: The BALANCE Model launches January 1, 2027 and will run alongside the Bridge through 2027 Which Drugs Are Covered